$19.43
+0.5
(+2.64%)▲
Revenue is down for the last 2 quarters, 238.0K → 206.0K (in $), with an average decrease of 13.5% per quarter
Netprofit is up for the last 2 quarters, -123.95M → -52.79M (in $), with an average increase of 134.8% per quarter
In the last 3 years, Moderna Inc has given 31.5% return, outperforming this stock by 90.8%
3.47%
Downside
Day's Volatility :3.77%
Upside
0.31%
54.71%
Downside
52 Weeks Volatility :74.22%
Upside
43.07%
Period | Bioxcel Therapeutics | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -35.53% | 1.3% | -6.9% |
6 Months | 5.77% | -4.8% | -2.4% |
1 Year | 79.91% | 0.7% | -6.4% |
3 Years | -60.85% | 26.7% | 17.4% |
Market Capitalization | 552.0M |
Book Value | $1.82 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -6.64 |
Wall Street Target Price | 53.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -30871.43% |
Return On Assets TTM | -57.32% |
Return On Equity TTM | -151.47% |
Revenue TTM | 581.0K |
Revenue Per Share TTM | 0.02 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 355.0K |
EBITDA | -179.0M |
Diluted Eps TTM | -6.64 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -6.79 |
EPS Estimate Next Year | -5.17 |
EPS Estimate Current Quarter | -1.62 |
EPS Estimate Next Quarter | -1.6 |
What analysts predicted
Upside of 172.77%
Sell
Neutral
Buy
Bioxcel Therapeutics is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Bioxcel Therapeutics | -26.21% | 5.77% | 79.91% | -60.85% | 79.74% |
![]() Moderna, Inc. | -2.16% | -25.72% | -7.93% | 118.1% | 593.01% |
![]() Regeneron Pharmaceuticals, Inc. | -0.25% | 0.37% | 23.19% | 24.21% | 138.08% |
![]() Seagen, Inc. | -1.53% | 65.54% | 36.96% | 29.38% | 198.64% |
![]() Vertex Pharmaceuticals Incorporated | -2.81% | 7.25% | 24.78% | 26.19% | 129.1% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Bioxcel Therapeutics | NA | NA | NA | -6.79 | -1.51 | -0.57 | 0.0 | 1.82 |
![]() Moderna, Inc. | 11.15 | 11.15 | 0.0 | -1.77 | 0.27 | 0.12 | 0.0 | 49.12 |
![]() Regeneron Pharmaceuticals, Inc. | 20.0 | 20.0 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
![]() Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
![]() Vertex Pharmaceuticals Incorporated | 25.77 | 25.77 | 0.41 | 13.58 | 0.26 | 0.17 | 0.0 | 56.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Bioxcel Therapeutics | Buy | $552.0M | 79.74% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $49.8B | 593.01% | 11.15 | 31.77% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $81.2B | 138.08% | 20.0 | 33.81% |
![]() Seagen, Inc. | Hold | $36.6B | 198.64% | NA | -31.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $86.0B | 129.1% | 25.77 | 35.4% |
FMR Inc
Adage Capital Partners Gp LLC
State Street Corporation
BlackRock Inc
Vanguard Group Inc
Artemis Investment Management LLP
Bioxcel Therapeutics’s price-to-earnings ratio stands at None
Read Morebioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.
Organization | Bioxcel Therapeutics |
Employees | 183 |
CEO | Dr. Vimal D. Mehta Ph.D. |
Industry | Health Technology |
Marathon Digital Holdings Inc
$9.19
-8.37%
MARBLEGATE ACQUISITION CORP.
$10.18
+0.0%
BLACK MOUNTAIN ACQUISITION-A
$10.55
+0.0%
BLOCKCHAIN COINVESTORS ACQUISITION CORP.
$10.51
+0.0%
IQ CHAIKIN US LARGE CAP ETF
$31.64
-1.75%
LARGO RESOURCES LTD
$3.84
+0.52%
LUTHER BURBANK CORP
$9.01
-4.05%
Standard Motor Products Inc
$35.95
-3.15%
Anfield Capital Diversified Alternatives ETF
$8.34
-0.24%